AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
Log in

NASDAQ:FLXNFlexion Therapeutics Stock Price, Forecast & News

$11.87
-0.30 (-2.47 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.73
Now: $11.87
$12.35
50-Day Range
$7.56
MA: $9.73
$12.18
52-Week Range
$5.01
Now: $11.87
$22.98
Volume28,062 shs
Average Volume1.28 million shs
Market Capitalization$457.71 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Read More
Flexion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$72.96 million
Book Value($0.53) per share

Profitability

Net Income$-149,770,000.00
Net Margins-175.76%

Miscellaneous

Employees288
Market Cap$457.71 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

How has Flexion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLXN shares have decreased by 3.7% and is now trading at $11.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Flexion Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Flexion Therapeutics.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Flexion Therapeutics.

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) issued its earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.95) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.05. The specialty pharmaceutical company earned $20.13 million during the quarter, compared to analysts' expectations of $18.45 million. Flexion Therapeutics had a negative return on equity of 592.50% and a negative net margin of 175.76%. View Flexion Therapeutics' earnings history.

What price target have analysts set for FLXN?

9 brokerages have issued twelve-month target prices for Flexion Therapeutics' stock. Their forecasts range from $17.00 to $35.00. On average, they expect Flexion Therapeutics' share price to reach $23.33 in the next year. This suggests a possible upside of 96.9% from the stock's current price. View analysts' price targets for Flexion Therapeutics.

Has Flexion Therapeutics been receiving favorable news coverage?

Media coverage about FLXN stock has been trending somewhat negative on Thursday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Flexion Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutFlexion Therapeutics.

Are investors shorting Flexion Therapeutics?

Flexion Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 8,200,000 shares, an increase of 15.5% from the April 15th total of 7,100,000 shares. Based on an average trading volume of 766,100 shares, the short-interest ratio is currently 10.7 days. Currently, 25.6% of the company's shares are short sold. View Flexion Therapeutics' Current Options Chain.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Cara Therapeutics (CARA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Inovio Pharmaceuticals (INO), Micron Technology (MU) and NVIDIA (NVDA).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 68, Pay $1.06M)
  • Dr. Neil Bodick, Consultant (Age 73, Pay $657.6k)
  • Dr. Scott D. Kelley, Chief Medical Officer (Age 61, Pay $626.53k)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 59)
  • Scott Young, VP of Corp. Communications & Investor Relations

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.71%), Wasatch Advisors Inc. (6.01%), State Street Corp (4.30%), Gagnon Securities LLC (1.88%), Granahan Investment Management Inc. MA (1.83%) and Schroder Investment Management Group (1.64%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman, Neil Bodick and Samuel D Colella. View institutional ownership trends for Flexion Therapeutics.

Which institutional investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Spark Investment Management LLC, UBS Group AG, State Street Corp, Gagnon Securities LLC, Parametric Portfolio Associates LLC, Victory Capital Management Inc., and Victory Capital Management Inc.. View insider buying and selling activity for Flexion Therapeutics.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Nuveen Asset Management LLC, Wasatch Advisors Inc., Two Sigma Investments LP, Raymond James Financial Services Advisors Inc., New York State Common Retirement Fund, Paradigm Capital Management Inc. NY, and Mesirow Financial Investment Management Inc.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Mark Stejbach, Michael D Clayman, and Samuel D Colella. View insider buying and selling activity for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $11.85.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $456.94 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.